The Baltimore Orioles have work to do in the rotation this offseason, but one trade idea floating around should be a hard pass.
Bleacher Report recently floated a deal that would send Spencer Strider and cash to Baltimore in exchange for outfielder Nate George and shortstop Wehiwa Aloy. On paper, it’s the kind of swing that can catch a team’s eye: Strider was once a top-tier arm, and the Orioles are staring at a winter where starting pitching has to be addressed.
They already gave long-term extensions to Shane Baz and Kyle Bradish over the last year, and Brandon Young’s rise gives them a solid three starters. But their highest-ceiling pitcher is headed for free agency, and Chris Bassitt also needs replacing.
That’s the problem. The free-agent market doesn’t offer much at the top, so the Orioles may have to look to trades if they want a real upgrade.
And Strider is the kind of name that will draw attention. The Braves were reportedly prepared to move him to the Rangers at the deadline in a deal for Jacob DeGrom before DeGrom declined to waive his no-trade clause, which is enough to put Strider back in the rumor mill.
Bleacher Report included him in its “ 6 Realistic MLB Trades That Could Happen in 2026-27 Offseason” piece, but Baltimore should think twice.
The reason is simple: the recent track record is rough. After brilliant 2022 and 2023 seasons that made him look like one of the game’s brightest young pitchers, Strider lost almost all of 2024 to the second major arm surgery of his career.
He returned in 2025, but the results weren’t the same - 23 starts, a 4.45 ERA, and 123 innings. He never got the chance to show whether that version was a true rebound, because 2026 was another short season.
This past year, Strider made only eight starts and posted a 5.31 ERA. He opened the season on the IL with an oblique injury, debuted in May, and then elbow inflammation shut him down for the rest of the year in June. The fastball also tells the story: his average velocity has dropped every season, sliding from 98.2 mph in 2022 to 95.1 in 2026.
The money makes it even tougher. Strider is in the middle of a heavily backloaded six-year, $75 million contract that began in 2023. He’s owed $22 million in each of the next two seasons, and the deal includes a club option for 2029 at the same amount, with a $5 million opt out.
That’s a lot of risk for an Orioles team that can’t afford to gamble on a pitcher whose health and effectiveness are both in question. If Baltimore is going to spend prospect capital, it needs to be on someone who can truly lift the ceiling of the rotation. With Strider, the injury history and the contract make that a very shaky bet.
In Other News...
Zach Eflin Just Put Baltimore In An Awkward Rotation Spot
Zach Eflins season never really got off the ground in Baltimore, and now the Orioles have a much larger rotation question hanging over them. He underwent Tommy John surgery in early April after exiting his first start with elbow discomfort, a brutal turn for a pitcher the club had planned to count on as part of its starting mix.
Eflins future with the Orioles now looks uncertain beyond the injury timeline, too. Baltimore is expected to buy out his 2027 mutual option for $2 million, which likely closes the door on his current deal, while Eflin is projected to miss a significant chunk of next season during rehab before possibly exploring a two-year free-agent contract once hes healthy again. For a team trying to map out its pitching depth, it leaves one less sure thing and another spot to sort out. [Read more 🡒]
Orioles Face A Bullpen Puzzle That Could Spark Real Debate
Before the season even got rolling, the Orioles were already dealing with a bullpen that looked short on certainty. Keegan Akin and Andrew Kittredge landed on the injured list before Opening Day, and closer Ryan Helsley also spent time there, a rough set of early blows for a group that was supposed to help stabilize games late.
Looking ahead, the bigger question is how Baltimore sorts out a relief mix that could still feature Helsley, Flix Bautista, Yennier Cano, Rico Garcia, Josh Walker and Grant Wolfram in 2027. Some of those arms arrived via trade or new deals, which only adds to the intrigue as the Orioles try to figure out which pieces are part of the long-term answer and which ones are just keeping the inning alive for now. [Read more 🡒]
Orioles Face A Bullpen Decision That Could Test Their Offseason
The Orioles are headed into an offseason that may ask more of their front office than any bullpen tweak in recent years. Baltimores relief corps has held up well enough to keep the club in the mix, but roster turnover is coming, and the late-inning group could look different before next spring. Around the league, teams like Tampa Bay have shown how a patchwork approach, built through trades, a Rule 5 Draft pick and a free-agent addition, can still produce meaningful bullpen depth when the pieces fit.
For Baltimore, the real challenge is not just replacing innings, but deciding how much certainty it can count on in a market that rarely makes relief pitching easy. Andrew Kittredge and Keegan Akin are both trending toward free agency, and Akin is also working back from Tommy John surgery from this past July, which adds another layer to an already unsettled picture. The Orioles have spent enough time chasing the margins to know how quickly a bullpen can change shape, and this winter may force them to prove they can do it again. [Read more 🡒]